Status:
COMPLETED
Escitalopram in Patients With Generalized Anxiety Disorder
Lead Sponsor:
H. Lundbeck A/S
Conditions:
Generalized Anxiety Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the effect of escitalopram after 8 weeks of treatment in patients with Generalized Anxiety Disorder (GAD), to evaluate proportion of patients who respond to es...
Detailed Description
The study will be performed in Russia, as an open-label, uncontrolled, one arm trial. The patients will receive escitalopram for 8 weeks. Start and maintenance dosages as well as dose titration will b...
Eligibility Criteria
Inclusion
- The patient suffers from GAD, diagnosed according to ICD-10 (International Classification of Diseases)
- The patient meets criteria as set out in the national SPC for escitalopram
- The patient is, in the opinion of the investigator, otherwise healthy on the basis of a physical examination, medical history and vital signs
Exclusion
- The patient has/has had an alcohol or drug abuse-related disorder, as defined in ICD-10
- The patient has contraindications to escitalopram
- The patient has a history of severe drug allergy or hypersensitivity, or known hypersensitivity to escitalopram
- The patient has a serious illness and/or serious sequelae thereof, including liver or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic, or metabolic disturbance
- The patient is pregnant or breast-feeding
- The patient, if a woman of childbearing potential, is not using adequate contraception
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00902564
Start Date
March 1 2009
End Date
March 1 2010
Last Update
June 10 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
RU001
Moscow, Russia